Abciximab

Administration

  • Type: Glycoprotein IIB/IIIA inhibitor
  • Dosage Forms: Injection
  • Routes of Administration: IV
  • Common Trade Names: Reopro

Adult Dosing

PCI Adjunct

  • 0.125 mcg/kg/min IV x 12h

Unstable angina, refractory

  • 10 mcg/min IV x 18-24h

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Benefits outweigh risks during pregnancy
  • Inadequate human data available to assess risk
  • Risk of maternal hemorrhage during delivery

Lactation risk

  • May use while breast feeding

Renal Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Contraindications

  • Allergy to class/drug
  • Hypersensitivity to murine proteins
  • Active internal bleeding
  • GI/GU bleeding w/in 6 weeks
  • Stroke w/in 2 years
  • Coagulation disorder
  • Plt < 100,000
  • INR > 1.2
  • Recent surgery or trauma
  • HTN, uncontrolled
  • Intracranial neoplasm, AVM, or aneurysm
  • Vasculitis hx
  • Dextran use in coronary procedure

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: <10 min initially then 30 min second phase
  • Metabolism: Other
  • Excretion: Urine

Mechanism of Action

Binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

Comments

See Also

References

Authors:

Jonathan Warren